[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kenneth A. Myszkowski CPA, CPA, MBA", "age": 58, "title": "Chief Financial Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 922626, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief of Discovery & Translational Medicine", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 70, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 9, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "maxAge": 86400, "priceHint": 2, "previousClose": 19.11, "open": 19.2705, "dayLow": 19.07, "dayHigh": 20.2, "regularMarketPreviousClose": 19.11, "regularMarketOpen": 19.2705, "regularMarketDayLow": 19.07, "regularMarketDayHigh": 20.2, "beta": 0.958, "forwardPE": -5.0617433, "volume": 894896, "regularMarketVolume": 894896, "averageVolume": 2081662, "averageVolume10days": 1439360, "averageDailyVolume10Day": 1439360, "bid": 19.88, "ask": 20.01, "bidSize": 200, "askSize": 100, "marketCap": 2515655168, "fiftyTwoWeekLow": 17.05, "fiftyTwoWeekHigh": 36.72, "priceToSalesTrailing12Months": 1006.2621, "fiftyDayAverage": 20.4778, "twoHundredDayAverage": 22.534275, "currency": "USD", "enterpriseValue": 2840354304, "floatShares": 111287888, "sharesOutstanding": 126098000, "sharesShort": 10062129, "sharesShortPriorMonth": 10006958, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.0805, "heldPercentInsiders": 0.04709, "heldPercentInstitutions": 0.81308997, "shortRatio": 3.82, "shortPercentOfFloat": 0.1071, "impliedSharesOutstanding": 126098000, "bookValue": 0.419, "priceToBook": 47.613365, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -639713984, "trailingEps": -5.15, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 1136.142, "enterpriseToEbitda": -4.684, "52WeekChange": -0.3459959, "SandP52WeekChange": 0.22903383, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ARWR", "underlyingSymbol": "ARWR", "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 756052200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "c1090240-5c7b-33ae-b362-c474642e552e", "messageBoardId": "finmb_203142", "gmtOffSetMilliseconds": -18000000, "currentPrice": 19.95, "targetHighPrice": 80.0, "targetLowPrice": 21.0, "targetMeanPrice": 45.78571, "targetMedianPrice": 41.5, "recommendationMean": 1.86667, "recommendationKey": "buy", "numberOfAnalystOpinions": 14, "totalCash": 550835008, "totalCashPerShare": 4.368, "ebitda": -606380032, "totalDebt": 872046016, "quickRatio": 5.902, "currentRatio": 6.085, "totalRevenue": 2500000, "debtToEquity": 1555.142, "revenuePerShare": 0.02, "returnOnAssets": -0.47709998, "returnOnEquity": -5.65332, "grossProfits": 2500000, "freeCashflow": -382800256, "operatingCashflow": -491283008, "revenueGrowth": -0.296, "grossMargins": 1.0, "operatingMargins": -64.5648, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]